Most Active

SELLAS Life Sciences Cancer Vaccine Cuts AML Death Risk 41% in Phase 3 Trial Sending Stock Up Over 280%

Read this in the Market Flux app

SELLAS Life Sciences Group, Inc. $SLS

$19.18+156.76%as of publication

5D Change
+129.15%
Notional
$2.17B

SELLAS Life Sciences shares surged more than 280% on November 17, trading above $28 on volume exceeding 200 million shares, after the company announced that its immunotherapeutic cancer vaccine galinpepimut-S (GPS) met the primary endpoint in the pivotal Phase 3 REGAL trial for acute myeloid leukemia (AML). The trial showed GPS reduced the risk of death by 41% compared with the best available treatment, posting a statistically significant hazard ratio of 0.59 (p=0.035). Median overall survival for GPS-treated patients reached 24.0 months versus 14.7 months for the control arm, a 9.3-month improvement.

The 126-patient REGAL trial focused on AML patients in second or later remission who were unable to undergo a stem cell transplant, a population with very limited treatment options. GPS, licensed from Memorial Sloan Kettering, is designed to stimulate the immune system to target residual leukemia cells expressing the WT1 protein. The vaccine was generally well tolerated, with mostly mild to moderate injection-site reactions and no new safety signals identified. The interim analysis was triggered by 80 events.

SELLAS said it plans to meet with the FDA to discuss an accelerated filing strategy, targeting a Biologics License Application submission in the first half of 2027. Full secondary endpoint results remain pending and GPS remains investigational. The stock's market cap reached approximately $6 billion following the announcement, and options activity was notable, with roughly $8.8 million in SLS calls trading in the first half hour of the session.

© AI-generated summary is provided by Market Flux

Sources

  1. BriefingcomGapping up: $SLS +257.4% $COHR +8.1% $ACM +7.4% $AAOI +7.3% $LITE +4.9% Gapping down: $RCAT -34.2% $JD -5.7% $SR -4.3% $WB -3.6%
  2. BPharmCatalyst$AYTU agreed to be acquired by Rosemont Pharmaceuticals for $2.70 per share in cash, representing a 41.1% premium to Aytu’s 30-day VWAP. The transaction provides a defined near-term valuation outcome and is expected to close in late December 2026, subject to tender conditions, warrant-related requirements and customary closing approvals. $SLS $AEON $GLSI $XRTX $AYTU $MDXG $MRKR $GTBP $CNTB $BDMD See More Pre-market Movers at BioPharmCatalyst in the Articles Menu
  3. Wallstengine$SLS +300% (Market cap: ~$6B) Sellas Life Sciences' experimental cancer vaccine extended survival in a pivotal Phase 3 leukemia trial, meeting its primary endpoint. Its vaccine, galinpepimut-S (GPS), reduced the risk of death by 41% compared with the best available treatment in patients with acute myeloid leukemia (AML), with a statistically significant hazard ratio of 0.59 (p=0.035). Median overall survival: • GPS vaccine: 24.0 months • Best available treatment: 14.7 months That's a 9.3-month improvement in median survival. The 126-patient REGAL trial focused on AML patients in their second or later remission who were unable to undergo a stem cell transplant, a group with limited treatment options. Licensed from Memorial Sloan Kettering, GPS is designed to stimulate the immune system to target residual leukemia cells expressing the WT1 protein. The vaccine was generally well tolerated, with mostly mild to moderate side effects, primarily injection-site reactions. No new safety concerns were identified. Sellas now plans to meet with the FDA to discuss an accelerated filing strategy, targeting a submission for approval in the first half of 2027. Full secondary endpoint results are still pending, and the vaccine remains investigational.
  4. OpenOutcrier$SLS (+234.7% pre) SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia
  5. CoinpediaSLS Stock Today Surges 281%
  6. NasdaqSELLAS Life Sciences Group, Inc. Announces Positive Phase 3 REGAL Trial Results for Galinpepimut-S
  7. BenzingaSELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,
  8. MarketRebelsOptions with increasing option implied volatility: $BITO $SLS $LABD $TECL $GDS $CMPS $LABU $TER $MRVL $INTC $MSTR $AMD $TSM $DRAM $FAZ
Show 2 more
  1. TheflynewsMidday Fly By: Home Depot replaces CEO, Huang willing to return to lead Nvidia $DIS $MDT $PEP $CSCO $TSN $KLAR $GFF $WW $FUBO $MFP $SLS $AS $TME $RCAT $OMER $JD $DB $GOOG $GOOGL $DASH $CART $AMZN $NVDA $HD $NKE $HUM $CVS $UNH $CI $CNC
  2. CheddarFlowIf you missed today's flow, here's the 6 most unusual trades from the session 🚨 $SPY Nov 20 740P: $13.7 MILLION+ of puts in 8 prints $QQQ Jan '27 640P: $11.4M in 3 sweeps, open interest was just 192 $NVDA puts: $8.9M across 18 buys ahead of earnings $SLS calls: $8.8M in the first half hour $QQQ Jan '27 630P: $6.6M in the first 10 minutes $SPY Mar '27 590P: 14 sweeps, $2.75M